OBJECTIVES This randomized controlled trial compares for the first time effects of Alvogyl versus absorbable gelatin sponge as palatal wound dressings on postoperative pain, amount of analgesic consumption, post-surgical bleeding, and wound re-epithelization. MATERIALS AND METHODS Following sample size calculation, 36 systemically healthy patients requiring palatal mucosal graft harvesting were randomized to receive Alvogyl (intervention group, 18 patients) or absorbable gelatin sponge (control group, 18 patients) palatal dressings. Patient-reported VAS pain scores over 2 weeks were defined as primary outcome. Post-surgical bleeding, number of analgesics consumed, and complete re-epithelialization of the palatal wound for up to 5 weeks were defined as secondary outcomes. RESULTS Although significantly higher VAS pain scores were reported in the control as compared with the intervention group up to 12 days post-surgically (from (median [range]) 8.5 [2-10] to 1 [0-2] and from 6 [0-10] to 0 [0-2] respectively), with higher analgesics consumption (from 2 [1-3] to 1 [0-3] and from 1 [0-3] to 0 [0-2] tablets respectively), a multivariate regression analysis considering age, gender, graft width/length, tissue thickness, analgesics intake, and dressing type demonstrated no statistically significant effect of any factor, including dressing type on VAS pain scores. At 4 weeks, 22.2% of patients in the intervention group versus 11.1% in the control group demonstrated complete re-epithelization of their palatal engraftment site, before complete re-epithelization in both groups at 5 weeks. No post-surgical bleeding was reported with both dressings. CONCLUSIONS Within the study's limitations, results suggest Alvogyl as a practical palatal surgical dressing, comparable with absorbable gelatin sponge in cost, pain reduction, hemostasis, and re-epithelization properties. TRIAL REGISTRATION www.ClinicalTrials.gov Identifier: NCT03402321 CLINICAL RELEVANCE: Alvogyl could present a novel palatal wound dressing material, comparable with gelatin sponge.

中文翻译：

---

上皮化游离牙龈移植物收获后，基和可吸收的明胶海绵作为pa伤口敷料：一项随机临床试验。

目的这项随机对照试验首次比较了Alvogyl和可吸收的明胶海绵作为pa伤口敷料对术后疼痛，止痛药用量，手术后出血和伤口再上皮形成的影响。材料和方法计算样本量后，将36例需要pa粘膜移植的全身健康患者随机接受Alvogyl（干预组，18例）或可吸收的明胶海绵（对照组，18例）的pa敷料。患者在2周内报告的VAS疼痛评分被定义为主要结局。手术后出血，消耗的止痛药数量以及complete伤口完全重新上皮（长达5周）被定义为次要结果。结果尽管与干预组相比，在术后12天（从（中位[范围]）8.5 [2-10]至1 [0-2]和6 [分别使用0-10]至0 [0-2]）和更高的镇痛剂消耗量（分别从2 [1-3]至1 [0-3]和1 [0-3]至0 [0-2]片剂） ），考虑年龄，性别，移植物宽度/长度，组织厚度，止痛剂摄入量和敷料类型的多元回归分析表明，包括敷料类型对VAS疼痛评分在内的任何因素均无统计学意义的影响。在第4周时，干预组的22.2％的患者与对照组的11.1％的患者表现出pa骨植入部位的完全上皮再生，而在第5周，两组的患者都完全上皮再生。两种敷料均无手术后出血的报道。结论在研究范围内，结果表明Alvogyl是一种实用的lat外科手术敷料，在成本，减轻疼痛，止血和再上皮化方面可与可吸收的明胶海绵媲美。试验注册www.ClinicalTrials.gov标识符：NCT03402321临床意义：Alvogyl可以提供一种与明胶海绵相当的新型pa伤口敷料。